Metastatic Breast Cancer
Conference Coverage
Treatment shows 'important improvements' in triple-negative breast cancer
Survival of patients without an initial diagnosis of triple-negative breast cancer was better with the antibody-drug conjugate, compared with...
From the Journals
Better survival with extended letrozole in early-stage breast cancer
Guidelines for duration of endocrine therapy ‘should be updated.’
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
Conference Coverage
Twelve-month overall survival benefit with ribociclib for metastatic breast cancer
It’s the first phase 3 trial to report a median overall survival beyond 5 years in advanced breast cancer.
Latest News
Flurry of cancer drug endorsements from EU panel
Approvals include pralsetinib for non-small cell lung cancer, ripretinib for advanced gastrointestinal stromal tumor, and zanubrutinib for...
From the Journals
Immunotherapy for cancer patients with poor PS needs a rethink
Patients should not receive immunotherapy just to reduce risk of side effects, doctor says.
From the Journals
A case is building for personalized, genome-based radiation dosing
The data so far “seem very solid. I’m very excited by the concept,” Dr. Brian Marples said.
Feature
Polygenic breast cancer risk scores strive to overcome racial bias
Efforts...
Recap
Therapeutic Approaches in Advanced Breast Cancer
Dr Susan Domchek, from the University of Pennsylvania, discusses the importance of identifying molecular characteristics of metastatic breast...
Conference Coverage
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer
Conference Coverage
ASCO 2021: Breast cancer sessions not to miss